Automate Your Wheel Strategy on NTRA
With Tiblio's Option Bot, you can configure your own wheel strategy including NTRA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NTRA
- Rev/Share 15.4291
- Book/Share 9.1276
- PB 24.9441
- Debt/Equity 0.1475
- CurrentRatio 3.2744
- ROIC -0.2405
- MktCap 31492925280.0
- FreeCF/Share 0.682
- PFCF 336.5887
- PE -101.0215
- Debt/Assets 0.1014
- DivYield 0
- ROE -0.2507
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NTRA | Citigroup | -- | Buy | -- | $300 | Jan. 7, 2026 |
| Resumed | NTRA | Morgan Stanley | -- | Overweight | -- | $265 | Dec. 2, 2025 |
| Upgrade | NTRA | BNP Paribas Exane | Underperform | Neutral | -- | $172 | Oct. 27, 2025 |
| Resumed | NTRA | Wells Fargo | -- | Equal Weight | -- | $175 | Sept. 22, 2025 |
| Initiation | NTRA | RBC Capital Mkts | -- | Outperform | -- | $251 | March 13, 2025 |
| Initiation | NTRA | Barclays | -- | Overweight | -- | $200 | Jan. 23, 2025 |
News
Natera Files Signatera CDx PMA With FDA for Bladder Cancer MRD Test
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
NTRA submits FDA PMA for Signatera CDx, aiming to guide bladder cancer treatment with MRD testing after positive phase 3 trial results.
Read More
Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Positive
Class A shares of the Alger Weatherbie Specialized Growth Fund outperformed the Russell 2500 Growth Index during the fourth quarter of 2025. Natera, Inc., ACADIA Pharmaceuticals Inc., and Glaukos Corp were among the top contributors to performance. FirstService Corp, AAR CORP., and Kratos Defense & Security Solutions, Inc. were among the top detractors from performance.
Read More
Alger Small Cap Focus Fund Q4 2025 Portfolio Update
Published: January 29, 2026 by: Seeking Alpha
Sentiment: Positive
Class A shares of the Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Guardant Health, Inc., and Natera, Inc. were among the top contributors to performance. Nebius Group, uniQure N.V., and Stevanato Group were among the top detractors from performance.
Read More
Alger Capital Appreciation Fund Q4 2025 Portfolio Update
Published: January 20, 2026 by: Seeking Alpha
Sentiment: Neutral
Class A shares of the Alger Capital Appreciation Fund underperformed the Russell 1000 Growth Index during the fourth quarter of 2025. Alphabet Inc., Western Digital Corporation, and Natera, Inc. were among the top contributors to performance. Nebius Group, Meta Platforms Inc, and Sea Limited were among the top detractors from performance.
Read More
Alger Spectra Fund Q4 2025 Portfolio Update
Published: January 19, 2026 by: Seeking Alpha
Sentiment: Negative
Class A shares of the Alger Spectra Fund underperformed the Russell 3000 Growth Index during the fourth quarter of 2025. Alphabet Inc., Natera, Inc., and Cidara Therapeutics, Inc. were among the top contributors to performance. Nebius Group N.V., Microsoft Corporation, and Meta Platforms Inc. were among the top detractors from performance.
Read More
NTRA & NVDA Partner to Improve AI Models for Precision Medicine
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Natera teams up with NVIDIA to train multimodal AI models, aiming to improve precision care through faster, scalable analysis of complex medical data.
Read More
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
Published: January 12, 2026 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a new collaboration with NVIDIA to accelerate the development of Natera's multimodal AI foundation model platform and expand applications across precision medicine. Under the collaboration, Natera will integrate its unique longitudinal and multi-time point in vivo datasets and proprietary machine learning models with NVIDIA's high-performance computing pla.
Read More
Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Published: December 22, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, Jan. 13, 2026 at 4:30 p.m. PT (7:30 p.m. ET). Members of management will deliver a presentation and host a Q&A with the investment community at the conference. A live webcast may be accessed through the investor relations section of the Natera websit.
Read More
Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks
Published: December 11, 2025 by: 24/7 Wall Street
Sentiment: Positive
Stanley Druckenmiller is a Wall Street legend whose trades are truly worth tracking due to how consistently he has been winning.
Read More
This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He's Buying Now.
Published: November 24, 2025 by: 24/7 Wall Street
Sentiment: Positive
Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing.
Read More
Natera, Inc. (NTRA) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Natera, Inc. ( NTRA ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM EST Company Participants Steve Chapman - CEO & Director Mike Brophy - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division So I am going to go ahead and kick it off. I'm Tycho Peterson from the Jefferies Life Science team.
Read More
Natera, Inc. (NTRA) Discusses Findings from ESMO Congress Transcript
Published: October 23, 2025 by: Seeking Alpha
Sentiment: Neutral
Natera, Inc. (NASDAQ:NTRA ) Discusses Findings from ESMO Congress October 23, 2025 8:00 AM EDT Company Participants Mike Brophy - Chief Financial Officer Alexey Aleshin - GM of Oncology and ECD & Chief Medical Officer Steve Chapman - CEO & Director Conference Call Participants Thomas Powles David Westenberg - Piper Sandler & Co., Research Division Colleen Babington - Wolfe Research, LLC Daniel Brennan - TD Cowen, Research Division Puneet Souda - Leerink Partners LLC, Research Division Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Presentation Operator Hello, and thank you for standing by.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer
Published: September 30, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a peer-reviewed manuscript in the Journal of Clinical Oncology - Precision Oncology (JCO PO). The paper features results from a multi-institutional study evaluating circulating tumor DNA (ctDNA) as a prognostic biomarker for patients with germ cell tumors (GCT), including testicular cancer. Testicular cancer represents approximately 95% of all.
Read More
Natera, Inc. (NTRA) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Natera, Inc. (NASDAQ:NTRA ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 10:30 AM EDT Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Eve Burstein - Sanford C. Bernstein & Co., LLC.
Read More
Can Natera Stock Reach $500?
Published: September 15, 2025 by: Forbes
Sentiment: Positive
Let's start with something remarkable. Natera (NASDAQ: NTRA) just marked its 10th anniversary as a public company, and what a journey it has been.
Read More
Natera, Inc. (NTRA) Presents At Baird Global Healthcare Conference 2025 Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Natera, Inc. (NASDAQ:NTRA ) Baird Global Healthcare Conference 2025 September 9, 2025 8:30 AM EDT Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Conference Call Participants Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Presentation Catherine Ramsey Senior Research Analyst All right, everyone.
Read More
Natera: A Buy As Positive Growth And Cashflow Outweigh Unprofitability
Published: September 02, 2025 by: Seeking Alpha
Sentiment: Positive
For my first rating of Natera, I called it a buy, while today's consensus seems to be between a hold and a strong buy. Both proven revenue growth and expected future growth outlooks are upside drivers, including positive cashflow, despite reported net losses. The company plays a key role in providing specialized testing solutions in the cancer-care and kidney-care space, among others.
Read More
Natera Shares Rise on the Launch of AI Platform for Precision Oncology
Published: August 25, 2025 by: Zacks Investment Research
Sentiment: Positive
NTRA shares gain after unveiling its in-house AI platform, built on vast oncology datasets to transform precision cancer care.
Read More
Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine
Published: August 22, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced the publication of more than 300 peer-reviewed papers featuring its technology and reinforcing its long-standing commitment to robust clinical evidence and scientific research. These publications span high-impact journals – such as Nature, Nature Medicine, the American Journal of Transplantation and American Journal of Obstetrics and Gynecology – and high.
Read More
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
Published: August 22, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of its proprietary AI foundation model platform. These models and applications, which were developed in-house, are designed to drive innovation across therapeutic development, from early target discovery to real-time clinical decision support. The platform features a modular, multimodal architecture composed of three integrated layers: Data foundation.
Read More
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
Published: August 18, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced positive topline results from the randomized, phase III IMvigor011 clinical trial in muscle-invasive bladder cancer (MIBC). The trial is sponsored by Genentech, a member of the Roche Group. IMvigor011 utilizes the Signatera ctDNA test in patients with MIBC to detect molecular residual disease (MRD) in the bloodstream after surgery and predict who will benefit fro.
Read More
TWST vs. NTRA: Which Genomics Play Is a Better Buy?
Published: July 25, 2025 by: 24/7 Wall Street
Sentiment: Positive
Cathie Wood's Ark funds have been really heating up in recent months. Perhaps her most intriguing and underrated fund is the Ark Genomics Revolution ETF (ARKG), which is packed full of extraordinary biotech innovators that could experience an AI tailwind like few other industries.
Read More
Nearly 16 % of Druckenmiller's Money Now Rides on This Stock
Published: June 05, 2025 by: 24/7 Wall Street
Sentiment: Positive
A high-growth gem is the largest holding in Stanley Druckenmiller's firm's fund.
Read More
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 - June 3, 2025 in Chicago, IL. Together with its collaborators, Natera will showcase the clinical utility of Signatera across 10 different cancer types. This extraordinary breadth of data includes analys.
Read More
Natera: The Clues In Q1 Earnings
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Positive
Natera delivered stellar Q1 results, with revenue and EPS beating expectations, and strong volume growth, especially for its flagship Signatera product. Management sees significant upside for Signatera, projecting it could become a $5 billion annual product as both volumes and ASPs rise. Natera consistently outperforms its own conservative guidance, suggesting future earnings beats are likely, especially with unmodeled 'true-up' revenue.
Read More
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Natera (NTRA) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at the 2025 ESMO Breast Cancer Annual Congress in Munich, Germany, taking place from May 14-17, 2025. Results from the I-SPY 2 clinical trial, sponsored and operated by Quantum Leap Healthcare Collaborative, will be shared in a mini-oral presentation on May 16, 2025. The report includes data from 712.
Read More
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) published a new study1 evaluating the performance of Prospera Heart with DQS to detect allograft rejection. Prospera with DQS leverages a two-threshold algorithm, combining the traditional donor fraction (dd-cfDNA %, measuring dd-cfDNA as a fraction of total cfDNA) and donor quantity score (DQS, estimating the to.
Read More
Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time
Published: March 17, 2025 by: Seeking Alpha
Sentiment: Positive
Natera Inc. shows robust growth with high margins, a strong genetic testing portfolio, and a recent pullback offering an attractive entry point for investors.
Read More
About Natera, Inc. (NTRA)
- IPO Date 2015-07-01
- Website https://www.natera.com
- Industry Medical - Diagnostics & Research
- CEO Steven Leonard Chapman
- Employees 4424